Ketamine's antidepressive effects tied to opioid system in brain, scientists say

August 29, 2018, Stanford University Medical Center
3-D model of Ketamine. Credit: Wikipedia

Scientists at the Stanford University School of Medicine have discovered that ketamine works as an antidepressant at least in part by activating the brain's opioid system.

The finding overturns previously held beliefs that the drug's antidepressant effects stemmed solely from its impact on the glutamate system. These beliefs led to the widespread use of ketamine to treat depression and spurred the development of glutamate-blocking drugs for use as antidepressants.

The new finding also highlights the interaction between depression, pain and addiction and presents an opportunity for clinicians to reframe treatment approaches for three of the most important public health crises today.

The research is believed to be the first to address how ketamine works in the human brain to provide relief from depression. A paper describing the work will be published Aug. 29 in The American Journal of Psychiatry.

"Before we did the study, I wasn't sure that ketamine really worked to treat depression. Now I know the drug works, but it doesn't work like everyone thought it was working," said Alan Schatzberg, MD, the Kenneth T. Norris Jr. Professor of Psychiatry and Behavioral Sciences, who shares senior authorship of the paper with Carolyn Rodriguez, MD, Ph.D., assistant professor of psychiatry and behavioral sciences.

Ketamine's origins

Ketamine was developed in the 1960s and has been used for decades as an anesthetic during surgery. It can cause dissociative side effects, including hallucinations, and has been used as a recreational drug. If used regularly, it can lead to dependence.

Although the Food and Drug Administration has not approved the drug's use for depression, some doctors have prescribed it "off-label" in recent years as a rapid but short-acting antidepressant. Traditional antidepressants, such as selective serotonin reuptake inhibitors, take four to six weeks to have an effect but don't work in two-thirds of patients who try them. Stand-alone ketamine clinics have popped up all over the country to administer expensive intravenous infusions of ketamine to patients, even though some scientists caution that not enough is known about the drug to warrant its widespread use for depression.

Ketamine infusions are also used to treat chronic pain, which is a common condition in depressed patients. Exactly how ketamine blunts pain is not fully understood, but it is known to work at least in part on the opioid system. The Stanford researchers wanted to see if the antidepressive effects of ketamine were also generated by ketamine's activation of the opioid system. They sought to answer this question through a small clinical trial in which people with depression were given an opioid-receptor blocker prior to taking ketamine.

The study enrolled adults with treatment-resistant depression, meaning their condition had not improved after multiple treatment efforts. Twelve participants received infusions of ketamine twice—once preceded by naltrexone, an opioid-receptor blocker, and once with placebo. Neither the study participants nor the researchers were told whether active drug or placebo was administered during each test. The researchers found that ketamine reduced depressive symptoms by about 90 percent for three days in more than half of the participants when administered with a placebo, but had virtually no effect on depressive symptoms when it was preceded by naltrexone.

"This was purely a mechanistic study, not a treatment trial," said Nolan Williams, MD, clinical assistant professor of psychiatry and behavioral science. "And the results were so clear that we ended the study early to avoid exposing additional patients to the ineffective combination treatment." Williams shares lead authorship of the paper with Boris Heifets, MD, Ph.D., clinical assistant professor of anesthesiology, perioperative and pain medicine.

Because the field of anesthesia has long regarded ketamine specifically as a nonopioid drug, Heifets was skeptical when Williams approached him about joining the research effort. "Everything that I was taught, and everything that I've always taught my students—all of the evidence supports the fact that ketamine is not an opioid," he said. "I was really surprised at the results."

Understanding how it works

Although some small studies have shown that ketamine had rapid, although transient, antidepressant effects, Schatzberg said the researchers wanted to understand how ketamine works. He said he came to suspect that ketamine's effects might be linked to the brain's opioid system when Rodriguez published a report on ketamine's ability to reduce symptoms of obsessive compulsive disorder, which was similar to previous Stanford research using the opioid morphine.

The prevailing hypothesis for ketamine's was that the blocked a receptor for glutamate, an excitatory neurotransmitter in the brain that is implicated in memory and learning. "But ketamine's mechanism is complicated, as it acts on many different receptor types beyond glutamate receptors, and it acts in three distinct phases—rapid effects, sustained effects and return to baseline," Rodriguez said.

Schatzberg noted that no other glutamate-receptor blocker has an antidepressant effect like ketamine and that attempts to develop similar drugs have largely failed.

The researchers said the findings from the new study may explain why ketamine works so quickly as an antidepressant: It activates the brain's during its first phase of activity. The glutamate system may be responsible for the sustaining effects after ketamine is metabolized, they said.

The authors say that revealing the role of the opioid system in the antidepressant effects of ketamine is critical in the effort to develop new antidepressants. For instance, glutamate receptor blockers may not have rapid antidepressant effects unless they also involve the opioid system, Williams said.

"Psychiatry used opioids, barbiturates and high doses of stimulants to treat depression 50 or 60 years ago," Schatzberg said. "We have to properly examine the risks associated with using drugs of abuse—even in low doses—to treat depression. It's not limited to ; other antidepressant drugs that target the opioid system are in development now, too."

While a standard opioid like morphine initially has an antidepressant effect, it promotes depression after repeated use, Williams said. People who are depressed take as much as 2.4 times as many opioids immediately after painful surgeries than those who aren't depressed, he said. "There is truly a link between , pain and opioid use," Heifets said. "You can't go after one without addressing the others."

Explore further: Antidepressant response within hours? Experts weigh evidence on ketamine as fast-acting treatment for depression

More information: American Journal of Psychiatry (2018). DOI: 10.1176/appi.ajp.2018.18020138

Related Stories

Antidepressant response within hours? Experts weigh evidence on ketamine as fast-acting treatment for depression

February 22, 2018
Recent studies suggest that ketamine, a widely used anesthetic agent, could offer a wholly new approach to treating severe depression—producing an antidepressant response in hours rather than weeks. Two reviews of recent ...

Discovery of ketamine's effect on depression is tempered with caution

May 1, 2018
In the early 1990s, Yale researchers noticed that chronically depressed patients experienced almost immediate—if transitory—relief from symptoms after taking the pediatric anesthetic ketamine. Their subsequent research ...

Ketamine acts fast to treat depression and its effects last—but how?

June 21, 2018
In contrast to most antidepressant medications, which can take several weeks to reduce depressive symptoms, ketamine—a commonly used veterinary anesthetic—can lift a person out of a deep depression within minutes of its ...

Ketamine has potential therapeutic role in adolescents with treatment-resistant depression

August 1, 2018
A new study has shown a significant average decrease in the Children's Depression Rating Scale (42.5%) among adolescents with treatment-resistant depression (TRD) who were treated with intravenous ketamine. The study, which ...

Low-dose ketamine may be an effective alternative to opioids

July 18, 2018
Opioids are commonly prescribed in the emergency department (ED) for the treatment of acute pain, but due to the epidemic of opioid misuse, analgesic alternatives are being explored. A new Academic Emergency Medicine analysis ...

Suicidal thoughts rapidly reduced with ketamine, finds study

December 14, 2017
Ketamine was significantly more effective than a commonly used sedative in reducing suicidal thoughts in depressed patients, according to researchers at Columbia University Medical Center (CUMC). They also found that ketamine's ...

Recommended for you

People can handle the truth (more than you think)

September 19, 2018
Most people value the moral principle of honesty. At the same time, they frequently avoid being honest with people in their everyday lives. Who hasn't told a fib or half-truth to get through an awkward social situation or ...

Mindfulness meditation: 10 minutes a day improves cognitive function

September 19, 2018
Practising mindfulness meditation for 10 minutes a day improves concentration and the ability to keep information active in one's mind, a function known as "working memory". The brain achieves this by becoming more efficient, ...

Close intercultural romantic relationships and friendships can boost creativity

September 19, 2018
You've worked abroad. You've lived abroad. But have you had a close friendship or romantic relationship with a person from a culture drastically different from your own?

The 'real you' is a myth – we constantly create false memories to achieve the identity we want

September 19, 2018
We all want other people to "get us" and appreciate us for who we really are. In striving to achieve such relationships, we typically assume that there is a "real me". But how do we actually know who we are? It may seem simple ...

Study reveals cannabinoid drugs make pain feel 'less unpleasant, more tolerable'

September 19, 2018
Researchers in the College of Arts and Sciences have determined that cannabinoid drugs do not appear to reduce the intensity of experimental pain, but, instead, may make pain feel less unpleasant and more tolerable.

New research helps to instill persistence in children

September 19, 2018
Encouraging children "to help," rather than asking them to "be helpers," can instill persistence as they work to fulfill daily tasks that are difficult to complete, finds a new psychology study.

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

granville583762
5 / 5 (2) Aug 29, 2018
Ketamine its Contraindications
Ketamine, used for anaesthesia induces a trance-like state providing pain relief, sedation, and memory loss The effects not lasting long, cause's a loss of feeling in the body and paralysis of the muscles leading to an experience of a distortion of reality giving a floating detached feeling changing how you see and hear things causing hallucinations, confusion, agitation, panic attacks, depression and long term memory, increasing both heart rate and blood pressure where its hallucinations increase psychiatric disorders.
@phys.org While a standard opioid like morphine initially has an antidepressant effect, it promotes depression after repeated use.

Antidepressants are used for nerve pain, as anyone who's been described for referred hip dysplasia nerve pain, antidepressant make you depressed and scatty, the complete opposite of their prescribed use for curing depression which applies to Ketamine.
Old_C_Code
5 / 5 (1) Aug 29, 2018
Uh oh, they used the word opioid in the study. Now the 12-year-old brains at DEA can attack the victims using this drug.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.